Collegium Pharmaceutical Inc（COLL）财务数据COLLCollegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. (COLL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Azstarys, accounting for 106.5% of total sales, equivalent to $212.79M. Other significant revenue streams include Nucynta IR and Belbuca. Understanding this composition is critical for investors evaluating how COLL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Collegium Pharmaceutical, Inc. maintains a gross margin of 55.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.60%, while the net margin is -7.53%. These profitability ratios, combined with a Return on Equity (ROE) of 17.61%, provide a clear picture of how effectively COLL converts its operational activities into shareholder value.

In the context of the broader market, COLL competes directly with industry leaders such as ARDX and OBX. With a market capitalization of $718.87M, it holds a significant position in the sector. When comparing efficiency, COLL's gross margin of 55.18% stands against ARDX's 95.24% and OBX's N/A. Such benchmarking helps identify whether Collegium Pharmaceutical, Inc. is trading at a premium or discount relative to its financial performance.

Collegium has shown strong revenue growth, particularly in its ADHD product line, which saw a 41% year-over-year increase. The gross margin has been robust, reaching 62.49% in Q4 2025, although recent quarterly performance has shown some volatility with a net income drop in Q2 2026.